Exhibition, Quarterly Reports, Lawsuit, and Service Launch - Research Report on Zoetis, United Therapeutics, BioReference, ICON,

 Exhibition, Quarterly Reports, Lawsuit, and Service Launch - Research Report
        on Zoetis, United Therapeutics, BioReference, ICON, and Abaxis

PR Newswire

NEW YORK, October 25, 2013

NEW YORK, October 25, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Zoetis
Inc. (NYSE: ZTS), United Therapeutics Corporation (NASDAQ: UTHR), BioReference
Laboratories Inc. (NASDAQ: BRLI), ICON Public Limited Company (NASDAQ: ICLR),
and Abaxis, Inc. (NASDAQ: ABAX). Today's readers may access these reports free
of charge - including full price targets, industry analysis and analyst
ratings - via the links below.

Zoetis Inc. Research Report

On October 22, 2013, Zoetis Inc. (Zoetis) announced that it is supporting the
"Animal Connections: Our Journey Together" exhibition on wheels. Zoetis
reported that "Animal Connections" is a custom-built exhibition housed on an
18-wheel truck that expands into 1,000 square feet of space, which offers free
admission from 10:00 a.m. to 4:00 p.m., however, pets are not allowed inside
the truck. According to Zoetis, the exhibition will be on view on the National
Mall between the Smithsonian Castle and the Smithsonian's National Museum of
Natural History beginning Saturday, October 26, 2013 through Monday, October
28, 2013 before moving near the US Botanic Garden on Tuesday, October 29,
2013. Clint Lewis, Executive Vice President and President of US business at
Zoetis, stated, "As part of our commitment to veterinarians, we are proud to
join with the Smithsonian and the AVMA in supporting 'Animal Connections' as a
means to inspire young people to pursue careers in veterinary medicine and its
allied professions." The Full Research Report on Zoetis Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/7e25_ZTS]

--

United Therapeutics Corporation Research Report

On October 22, 2013, United Therapeutics Corporation (United Therapeutics)
announced that it will release its Q3 2013 results before the market opens on
Tuesday, October 29, 2013. United Therapeutics reported that the release will
be followed by its Q3 2013 conference call on the same day, at 9:00 a.m. ET.
The Company informed that interested parties may access the webcast through
its Investor Relations website or listen to the live call through the
designated dial-in lines. The Full Research Report on United Therapeutics
Corporation - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/e4cc_UTHR]

--

BioReference Laboratories Inc. Research Report

On October 22, 2013, BioReference Laboratories Inc. (BioReference) announced
that Myriad Genetics has filed a lawsuit against it in the Federal District
Court in Utah alleging that BioReference, through its genetic sequencing
laboratory, GeneDx, Inc., is infringing on its intellectual property by
offering OncoGeneDx, its comprehensive series of inherited cancers testing,
including testing for BRCA1/2. BioReference further indicated that it is not
surprised by the action and that it is confident in its position. According to
the Company, it is fully prepared to face Myriad Genetics in court with the
help of Sterne, Kessler, Goldstein & Fox. The Full Research Report on
BioReference Laboratories Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/1f59_BRLI]

--

ICON Public Limited Company Research Report

On October 9, 2013, ICON Public Limited Company (ICON) launched ICONIK Patient
Safety, the latest service to leverage its ICONIK technology platform. ICON
reported that ICONIK Patient Safety offers a systematic way to monitor safety
trends in accumulating data, spot potential safety issues and take appropriate
corrective and preventative action while the study is on-going. Dr. Peter
Schueler, Senior Vice President Medical and Safety Services, ICON Clinical
Research, said, "Patient wellbeing is paramount in any clinical trial. ICONIK
Patient Safety allows real-time review of integrated patient safety data,
thereby improving our ability to identify and monitor unexpected adverse
events. ICONIK Patient Safety helps study teams maintain a view of a drug's
evolving safety profile by accumulating safety data in real-time and allowing
for quick identification of emerging safety issues, affording greater
protection of patients' well-being. Before ICONIK Patient Safety, this level
of dynamic analysis and management of patient safety was simply not possible."
The Full Research Report on ICON Public Limited Company - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/fbb0_ICLR]

--

Abaxis, Inc. Research Report

On October 22, 2013, Abaxis, Inc. (Abaxis) released its Q2 FY 2014 results
(period ended September 30, 2013). Abaxis registered revenues of $45.9
million, up 3.6% YoY in Q2 FY 2014. The Company's net income was $4.0 million
in Q2 FY 2014, compared to net income of $12.9 million in Q2 FY 2013. Abaxis
posted diluted EPS of $0.18 for Q2 FY 2014, compared to diluted EPS of $0.58
in Q2 FY 2013. The Full Research Report on Abaxis, Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/ec55_ABAX]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

SOURCE Analysts' Corner

Contact: CONTACT PERSON: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North
America)
 
Press spacebar to pause and continue. Press esc to stop.